The short version of purity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-02. Anything still debated is marked as such rather than presented as settled.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | GHRH receptor agonist |
| Sequence length | 29 amino acids | Derived from human GHRH |
| Molecular weight | About 3368 Da without linker | Albumin-binding form is heavier |
| Appearance | White to off-white lyophilized powder | Common form for research reference material |
| Typical storage | -20 °C or below, desiccated | Protect powder from light and moisture |
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
In March 2015, Spotlight entered into a purchase agreement with Memcine Pharmaceuticals, Inc., a Coralville, Iowa-based biotech company specializing in vaccine efficacy. Memcine Pharmaceuticals would officially become a Spotlight Innovation subsidiary in June 2015. In April 2015, Spotlight Innovation secured $2.5 million in financing from an unsecured convertible promissory note. In October 2016, Spotlight Innovation announced that it was discontinuing the Memcine Pharmaceuticals Immunoplex development program. In August 2016 Spotlight Innovation entered into a sponsored research agreement with Florida State University to support the work of Professor Hengli Tang in the development of treatments for Zika virus infection. In October 2016, Spotlight Innovation announced the formation of subsidiary Caretta Therapeutics, LLC. Caretta Therapeutics is based in Urbandale, Iowa. The subsidiary develops and markets over-the-counter (OTC) analgesic products formulated to provide relief from chronic pain associated with inflammation. In October 2016, Spotlight Innovation obtained an exclusive license from Indiana University Research and Technology Corp to commercialize an orally available small molecule named STL-182 with potential therapeutic potential for the treatment of spinal muscular atrophy. Early preclinical testing of STL-182 was accomplished by Dr. Elliot Androphy of Indiana University School of Medicine and Professor Kevin Hodgetts of Brigham and Women's Hospital.
Medications that have traditionally been known to lead to SJS, erythema multiforme, and toxic epidermal necrolysis include sulfonamide antibiotics, penicillin antibiotics, cefixime (antibiotic), barbiturates (sedatives), lamotrigine, phenytoin (e.g., Dilantin) (anticonvulsants), and trimethoprim. Combining lamotrigine with sodium valproate increases the risk of SJS. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a rare cause of SJS in adults; the risk is higher for older patients, women, and those initiating treatment. Typically, the symptoms of drug-induced SJS arise within a week of starting the medication. Similar to NSAIDs, paracetamol (acetaminophen) has also caused rare cases of SJS. People with systemic lupus erythematosus or HIV infections are more susceptible to drug-induced SJS.
Moreover, engineered knottins have shown significant promise as therapeutics, imaging agents, and targeting agents for chemotherapy. The mammalian proteins Agouti signalling peptide and Agouti related peptide are the only known mammalian examples of this motif. Both are neuropeptides involved in cell signalling. The former is responsible for hair (fur) colouration. The motif is similar to the cyclic cystine knot or cyclotide, but lacks the cyclisation of the polypeptide backbone which is present in the latter family. The growth factor cystine knot (GFCK) is similar to the ICK but its topology is such that it is the bond between the first and fourth disulfide which threads through the loop.
Sources: en.wikipedia.org
== Further reading == Bryant, Alfred T. (1964). A History of the Zulu and Neighbouring Tribes. Cape Town: C. Struik. p. 157. Cana, Frank Richardson (1911). "Zululand" . Encyclopædia Britannica. Vol. 28 (11th ed.). pp. 1050–1055. Morris, Donald R. (1965). The Washing of the Spears: the Rise of the Zulu Nation. New York: Simon and Schuster. p. 655. Deflem, Mathieu. (1999). Warfare, Political Leadership, and State Formation: The Case of the Zulu Kingdom, 1808–1879. Ethnology 38(4):371–391. Knight, Ian. (2010). Zulu Rising: The Epic Story of Isandlwana and Rorke's Drift, London: Macmillan. ISBN 978-1-405-09185-5
== Academic background == Gerngross received a M.S. (Dipl. Ing.) in chemical engineering (1989) and later a Ph.D. in molecular biology from the Technical University of Vienna, Austria. Following his studies in Austria he became a visiting scientist at the Massachusetts Institute of Technology in the laboratory of the late Arnold Demain (1989–91) and later joined the laboratory of Anthony Sinskey and JoAnne Stubbe at MIT as a postdoctoral associate from 1991 to 1993. From 1993 till 1998 he headed the fermentation and process development group at Metabolix Inc., a small startup company in Cambridge, Massachusetts. In 1998 he left industry to join the faculty at Dartmouth where he focused his research on protein engineering, glycoprotein engineering in yeast, and life cycle analysis of competing manufacturing technologies. In addition to this work, Gerngross’ lab also developed a novel protein expression system based on the industrial fermentation organisms Ralstonia eutropha, formerly Alcaligenes eutrophus. With certain model proteins, this expression system has shown to outperform E. coli, the well proven workhorse of prokaryotic protein expression. The work on Ralstonia eutropha was later expanded in collaboration with Prof. Wood at Princeton University to combine recombinant expression of proteins with the ability to purify them in vivo. In the late 1990s Gerngross became one of the first vocal critics of biobased processes.
This unit is still in development phase at the time of writing but is significant as it has the potential to run much higher compression ratios than even other rotary valve engines due to a significant but undisclosed new cooling method of the combustion chamber and the ability to eliminate the throttle completely, making it vastly more economical at lower engine speeds, so it is claimed. A proven automotive rotary valve engine was developed by Ralph Ogden Watson of Auckland New Zealand, during 1989. Since its inception, the car with the rotary valve has covered many trouble-free miles and remains in use.
== External links == Overview of all the structural information available in the PDB for UniProt: P25116 (Proteinase-activated receptor 1) at the PDBe-KB. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Sources: en.wikipedia.org
=== United Kingdom === Lycium barbarum had been introduced in the United Kingdom in the 1730s by The Duke of Argyll, but the plant was mostly used for hedges and decorative gardening. The UK Food Standards Agency (FSA) had initially placed goji berry in the Novel Foods list. That classification would have required authorisation from the European Council and Parliament for marketing. However, on 18 June 2007, the FSA concluded that there was a significant history of consumption of the fruit before 1997, indicating its safety, and thus removed it from the list.
A statistical analysis plan is a document that contains a more technical and detailed elaboration of the principal features of the analysis described in the protocol, and includes detailed procedures for executing the statistical analysis of the primary and secondary variables and other data. (ICH E9) Statistical significance
== Clinical significance == Truncation mutations in MYBPC3 stand as the primary cause of hypertrophic cardiomyopathy (HCM). To date, roughly 350 mutations in MYBPC3 have been identified, and in large part, the mutations result in protein truncation, shifts in reading frames, and premature termination codons. Genetic studies have revealed significant overlap between genotypes and phenotypes as MYBPC3 mutations can lead to various forms of cardiomyopathies, such as dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy. In patients with isolated or familial cases of dilated cardiomyopathy, MYBPC3 mutations represented the second highest number of known mutations. Furthermore, a 25-bp intronic MYBPC3 deletion leading to protein truncation is present in 4% of the population in South India and is associated with a higher risk to develop heart failure. Founder MYBPC3 mutations have been reported in Iceland, Italy, The Netherlands, Japan, France and Finland, where they represent a large percentage of cases with hypertrophic cardiomyopathy. All of them are truncating mutations, resulting in a shorter protein, lacking the regulatory phosphorylatable M motif and/or major binding domains to other sarcomeric proteins. A body of evidence indicates that patients with more than one mutation often develop a more severe phenotype, and a significant fraction of childhood-onset hypertrophic cardiomyopathy (14%) is caused by compound genetic variants. This suggests that a gene-dosage effect might be responsible for manifestations at a younger age.
Sources: en.wikipedia.org
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.
The label was first attached to the albumin-binding form during early development work. A shorter analog without the linker later became known by the same name in informal use. Published papers normally state which version was studied, so the methods section resolves the ambiguity.
It is a synthetic peptide rather than a steroid, and it does not occur naturally in the body. Its sequence is derived from a hypothalamic hormone called growth hormone-releasing hormone. It works as a receptor agonist rather than as a replacement for that hormone.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.